SYRS (Syros Pharmaceuticals) Cash-to-Debt : 0.97 (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Syros Pharmaceuticals's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.97.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Syros Pharmaceuticals couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Syros Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

SYRS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.97 Med: 3.53 Max: 13526.78
Current: 0.97

During the past 10 years, Syros Pharmaceuticals's highest Cash to Debt Ratio was 13526.78. The lowest was 0.97. And the median was 3.53.

SYRS's Cash-to-Debt is ranked worse than
76.6% of 1487 companies
in the Biotechnology industry
Industry Median: 7.48 vs SYRS: 0.97

Syros Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Syros Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Syros Pharmaceuticals Cash-to-Debt Chart

Syros Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

3.53

2.63

2.00

3.18

2.25

Syros Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															1.80	2.25	1.76	1.30	0.97

Competitive Comparison of Syros Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Syros Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syros Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Syros Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Syros Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	139.526	/	(8.991	+	53.084)
	=	2.25

Syros Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	58.275	/	(2.584	+	57.642)
	=	0.97

Syros Pharmaceuticals (OTCPK:SYRS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Syros Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Syros Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (OTCPK:SYRS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

0LC7:UK 0S90:Germany

Address

35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140

Website

https://www.syros.com

Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Executives

Nancy A Simonian	director, 10 percent owner, officer: President & CEO	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Gerald E Quirk	officer: Chief Legal Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David Roth	officer: Chief Medical Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jason Haas	officer: Chief Financial Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Kristin Stephens	officer: Chief Development Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley	officer: Chief Commercial Officer	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Eric R Olson	officer: Chief Scientific Officer	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson	director	ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh	director	C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Deborah Dunsire	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Richard A Young	director	C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt	director	C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn	officer: Chief Business Officer	C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421